Roivant Sciences (ROIV) just posted its FY 2026 third quarter scorecard, with total revenue of US$2.0 million and a basic EPS loss of US$0.38, set against a trailing 12 month basic EPS loss of US$1.17 and revenue of US$13.31 million. Over recent periods the company has seen quarterly revenue move between US$4.48 million and US$9.02 million in FY 2025, while quarterly basic EPS losses have ranged from US$0.17 to US$0.33. That combination of modest top line and sizable losses keeps the focus squarely on whether margins can tighten enough to justify the growth story implied by the pipeline and forecasts.

See our full analysis for Roivant Sciences.

With the latest numbers on the table, the next step is to see how this earnings profile lines up with the widely discussed growth, risk and valuation narratives around Roivant Sciences.

Losses Stay Heavy At US$809 Million LTM

• Over the trailing 12 months, Roivant reported a net loss of US$809.24 million and a basic EPS loss of US$1.17, with the latest quarter alone showing a net loss of US$265.89 million on revenue of US$2.0 million.
• Bulls point to managements view that multiple late stage programs could support earnings over time. This thesis sits against current losses where analysts today expect earnings of US$292.3 million by around 2028 and an implied P/E of 88.3x on those earnings, so the scale of the turnaround embedded in the optimistic case is very large relative to the present EPS loss of US$1.17 over the last year.
  • Consensus narrative highlights a projected US$264.2 million in earnings by 2029 and an implied P/E of 138.6x on those earnings, which is far above the current stated US Biotechs industry P/E of 17.3x.
  • Against that backdrop, the current loss of US$809.24 million means the bullish and consensus scenarios assume a multi hundred million dollar swing in profitability compared with the latest trailing data.

Pipeline Build Out vs Current Spend

• The company is carrying an extensive late stage portfolio, with 7 products in Phase II, 3 in Phase III and 1 in pre registration at FY 2026 Q3, alongside quarterly net losses ranging from US$113.52 million to US$265.89 million across FY 2026 so far.
• Bulls argue that 11 late stage programs and planned launches over the next few years could build significant revenue. The current quarterly net losses of US$223.36 million, US$113.52 million and US$265.89 million across the first three quarters of FY 2026 show how much spending is still required to support that pipeline, so investors need to weigh the breadth of trials against the reality that earnings remain negative today.
  • Optimistic analysts reference a potential portfolio with very large peak sales, while the financials currently show trailing 12 month revenue of just US$13.31 million.
  • This gap between a late stage pipeline and modest reported revenue is central to the bullish case that successful approvals and launches could eventually support higher operating scale than the present income statement reflects.

Curious how much of that earnings swing is already priced in and what would need to go right across all those trials to justify it? According to bullish investors, the dedicated bull narrative lays out that version of the story in one place. 🐂 Roivant Sciences Bull Case

DCF Upside Meets Rich P/B Multiple

• Roivant shares trade at a P/B of 5.4x versus peer and US Biotechs averages around 2.1x to 2.3x, while a provided DCF fair value of US$87.72 sits well above the current share price of US$32.41.
• Bears focus on this tension, arguing that a P/B more than double peers creates valuation risk even if the DCF fair value stands at US$87.72, and that the trailing loss of US$809.24 million plus expectations that the company will remain unprofitable over the next three years leave limited support from near term earnings for such a premium multiple.
  • The concise risk summary flags that analysts do not forecast profitability over the coming three years, while the analyst price target referenced in the consensus framework is US$36.13, only modestly above the current share price of US$32.41.
  • This mix of premium P/B, ongoing losses and a relatively tight gap to the US$36.13 price target is what critics cite when questioning how much of the long term growth story is already reflected in the stock.

If you want to see exactly how cautious investors frame that valuation risk around the high P/B and ongoing losses, the bearish narrative sets out those concerns in detail. 🐻 Roivant Sciences Bear Case

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Roivant Sciences on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

Does this mix of optimism and concern match how you see Roivant today? Take a close look at the numbers, weigh both sides, and then check the 2 key rewards and 1 important warning sign

See What Else Is Out There

Roivant is carrying heavy losses, modest revenue and a rich P/B multiple, while analysts do not expect profitability over the next three years.

If you want stocks where valuations lean on current fundamentals rather than distant profit targets, start comparing companies in the 51 high quality undervalued stocks today.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.